View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Gilead Sciences Inc: 1 director

A director at Gilead Sciences Inc sold/sold after exercising options 8,500 shares at 91.960USD and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's director...

Moody's Ratings assigns A3 rating to Gilead's notes; stable outlook

Moody's Ratings (Moody´s) assigned an A3 rating to the new senior unsecured notes issuance of Gilead Sciences, Inc. ("Gilead"). There are no changes to Gilead's existing ratings including the A3 senior unsecured ratings, (P)A3 senior unsecured shelf or the stable outlook. Proceeds of the offering ...

Gilead Sciences, Inc.: Update to credit analysis

Our credit view of this issuer reflects its status as a global market leader in HIV therapies, against its somewhat limited revenue diversity at the product and category level.

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Gilead Sciences, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 17 October 2024 in which we reassessed the appropriateness of the ratings in the cont...

Research Team ACF
  • Research Team ACF

ACF Insight - Innovations in Oncology - the Future of Cancer Treatment...

Global oncology spending is projected to reach US$409bn by 2028E, up from US$223bn in 2023A at a 5yr CAGR of 11.5-14.5% from 2024-2028 (IQVIA, 2024). This growth is in part driven by US spending, which has increased to $99bn in 2023A up from $65bn in 2019A - the US makes up ~45% of global oncology spending.

Research Team ACF
  • Research Team ACF

Regenerative Healthcare - Stem Cells & ALS Thematic 10062024

Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital. Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms. Within regenerative medicine we believe there ...

Moody's says Gilead's acquisition of CymaBay will enhance liver produc...

Moody's Investors Service commented that Gilead Sciences, Inc.'s announcement that it would acquire publicly-traded CymaBay Therapeutics, Inc. for approximately $4.3 billion will enhance Gilead's expertise in liver disease and provides a solid growth opportunity, a credit positive. At the same time,...

Gilead Sciences, Inc.: Acquisition of CymaBay will enhance liver produ...

CymaBay provides GIlead with a solid growth opportunity in selaldelpar with a minimal impact on key credit metrics.

Moody's announces completion of a periodic review of ratings of Gilead...

Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Gilead Sciences, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 4 January 2024 in which Moody's reassessed the appropriateness of the rati...

Gilead Sciences, Inc.: Steady growth in core HIV and oncology products...

Our credit view of this issuer reflects its status as a global market leader in HIV therapies, against its somewhat limited revenue diversity at the product and category level.

Moody's announces completion of a periodic review of ratings of Gilead...

Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Gilead Sciences, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 4 January 2024 in which Moody's reassessed the appropriateness of the rat...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 11, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

BAC BANK OF AMERICA CORP
ZBRA ZEBRA TECHNOLOGIES CORPORATION CLASS A
UAL UNITED AIRLINES HOLDINGS INC.
SEIC SEI INVESTMENTS COMPANY
SBCF SEACOAST BANKING CORPORATION OF FLORIDA
MKL MARKEL CORPORATION
MAA MID-AMERICA APARTMENT COMMUNITIES INC.
HUN HUNTSMAN CORPORATION
EL ESTEE LAUDER COMPANIES INC. CLASS A
DIN DINE BRANDS GLOBAL INC.
CVS CVS HEALTH CORPORATION
CNP CENTERPOINT ENERGY INC.
B BARNES GROUP INC.
APH AMPHENOL CORPORATION CLASS A
ALGN ALIGN TECHNOLOGY INC.
ALB ALBEMARLE CORPORATION
OSTK OVERSTOCK.COM INC.
AROW ARROW FINANCIAL CORP.
TEX TEREX CORPORATION
CYH COMMUNITY HEALTH SYSTEMS INC.
PETS PETMED EXPRESS INC.
UEIC UNIVERSAL ELECTRONICS INC.
FCPT FOUR CORNERS PROPERTY TRUST INC.
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
BSM BLACK STONE MINERALS LP
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
MSBI MIDLAND STATES BANCORP
XOM EXXON MOBIL CORPORATION
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
AES THE AES CORPORATION
CXH MFS INVESTMENT GRADE MUNICIPAL TRUST
BY BYLINE BANCORP
XPO XPO LOGISTICS EUROPE SA
MPB MID PENN BANCORP INC.
NWPP NEW PEOPLES BANKSHARES INC.
RBB RBB BANCORP
INTZ INTRUSION
EML THE EASTERN COMPANY
NVST ENVISTA HOLDINGS
GCI GANNETT CO. INC.
AMPY AMPLIFY ENERGY
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
KYMR KYMERA THERAPEUTICS
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
BALY BALLYS CORPORATION
DLHC DALEIGH HOLDINGS CORP
RPTX REPARE THERAPEUTICS
PACK RANPAK HOLDINGS (A)
LUMN LUMEN TECHNOLOGIES INC.
COFS CHOICEONE FINANCIAL SERVICES
LFMD LIFEMD
SOFI INC.
SRPT SOFI TECHNOLOGIES INC
KBR SAREPTA THERAPEUTICS
INC.
KBR
INC.
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch